After the slump on weak quarterly results, investors turned positive on Axsome Therapeutics (AXSM) stock, which climbed to the 34-month high of $11.33 on Monday. Traders were positive on the company’s patient enrollment in Migraine final trial as well as its commitment to developing therapies...